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SYSTEMIC INSULIN-LIKE growth factor (IGF-I) potently increases growth of the small intestine and colon, and elevated circulating IGF-I increases the risk of intestinal cancer (7) . Studies in transgenic mice that overexpress IGF-I demonstrate both endocrine and local autocrine or paracrine actions of IGF-I on bowel growth in vivo (15, 16, 25, 28) . Mice that overexpress a human IGF-I transgene driven by a mouse metallothionein-1 promoter (MT-hIGF-I transgenics) exhibit significant increases in small bowel length, mass of small bowel mucosa, and crypt cell proliferation (15) . These effects may derive from endocrine effects of the elevated circulating IGF-I that occur in this model or from autocrine or paracrine actions of transgenederived IGF-I, which is locally overexpressed in intestine of these mice (15) . SMP8-IGF-I transgenic mice have a rat IGF-I transgene driven by the smooth muscle ␣-actin SMP8 promoter. These mice have normal plasma levels of IGF-I but show high-level expression of the IGF-I transgene specifically in enteric smooth muscle layers, leading to overgrowth of muscularis layers (25, 28) .
The type 1 IGF receptor (IGF-IR) is the primary mediator of the growth-promoting effects of IGF-I in vitro and in vivo (3) . The IGF-IR is a receptor tyrosine kinase and is expressed throughout the intestine (11, 21) . IGF-I induces autophosphorylation of the IGF-IR and subsequent, rapid tyrosine phosphorylation of several early intracellular signaling proteins, including insulin receptor substrates (IRS-1 and IRS-2) and Src homology 2 domain and collagen protein (Shc) (3, 13) . Considerable in vitro evidence, derived largely from embryonic or cancer cell lines, indicates that IRS-1 is a major intracellular mediator of the proliferative and antiapoptotic actions of IGF-I (2, 3). Mice that are homozygous for IRS-1 gene deletion (IRS-1 Ϫ/Ϫ ) exhibit reduced body weight and reduced weight of a number of organs, but the magnitude of growth impairment differs among organs (16) . In IRS-1-null mice, the weight of the small intestine is preserved more than body weight or the weight of the gastrocnemius muscle but is impaired more than brain weight (16) . The intermediate growth dependence of the small intestine on IRS-1 prompted us to analyze intestinal growth in IRS-1-null mice in more detail to test the hypothesis that there are cell type-specific differences in the requirement for IRS-1 as an in vivo mediator of intestinal growth. We therefore examined growth of the mucosa and muscularis in the small intestine and colon of IRS-1-null mice and wild-type (WT) littermates.
Intestinal growth deficits in IRS-1-null mice may reflect impaired actions of IGF-I but could reflect impaired actions of other hormones that utilize IRS-1 as a signaling intermediate, including insulin or growth hormone (3, 16) . IGF-I transgenic mice cross-bred with IRS-1-null mice provide a useful model to directly assess whether the growth-promoting effects of IGF-I on the intestinal mucosa or muscularis layers in vivo require IRS-1. We therefore examined growth of colonic mucosa and muscularis layers in MT-hIGF-I transgenic or SMP8-IGF-I transgenic mice that have two functional IRS-1 alleles (IRS-1 ϩ/ϩ ) or are homozygous for IRS-1 gene disruption (IRS-1 Ϫ/Ϫ ). We focused our analyses on colon because initial studies in IRS-1-null mice revealed major growth deficits in both mucosa and muscularis layers of the colon. In addition, despite considerable evidence for a role of IGF-I in colorectal cancer (5), surprisingly little is known about the in vivo actions of IGF-I in normal colon or its mechanisms of action. Our findings provide novel evidence that IRS-1 deficiency impairs IGF-I action on the intestinal mucosa but not the muscularis. Moreover, we show that in vivo antiapoptotic but not proliferative actions of IGF-I on the crypt epithelium require IRS-1.
EXPERIMENTAL PROCEDURES

IRS-1
Ϫ/Ϫ , IRS-1 ϩ/Ϫ , and IRS-1 ϩ/ϩ mice. Founder mice heterozygous for targeted disruption of the IRS-1 gene (1) were provided by C. Ronald Kahn (Joslin Diabetes Center, Boston, MA). IRS-1 ϩ/Ϫ males and females were bred to generate mice with zero copies (IRS-1 Ϫ/Ϫ ), one copy (IRS-1 ϩ/Ϫ ), or two copies (IRS-1 ϩ / ϩ ) of the IRS-1 gene. Genotypes were identified by PCR on tail DNA as previously described (1, 16) . Analyses focused on mice with zero or two copies of the IRS-1 gene, because previous studies indicate only very small intestinal growth deficits in IRS-1 ϩ/Ϫ mice (16) . IRS-1 Ϫ/Ϫ mice were compared directly with IRS-1 ϩ/ϩ littermates to eliminate interlitter variation.
WT and IGF-I transgenic mice with zero or two copies of the IRS-1 gene. Transgenic mice with germline integration of a human IGF-I transgene driven by the mouse metallothionein-1 promoter (MThIGF-I) were generated in our laboratories (15) . Cross-breeding of IGF-I transgenics and mice with IRS-1 deficiency has been described in detail previously (16) . MT-hIGF-I and WT mice with zero or two functional IRS-1 alleles were analyzed. All mice were given 25 mM zinc sulfate in drinking water to ensure maximal expression of the metallothionein promoter-driven IGF-I transgene in MT-hIGF-I transgenics. Genotype of cross-bred animals was established by PCR on tail DNA (1, 16) . SMP8-IGF-I transgenic hemizygous males (25) were bred with IRS-1 ϩ/Ϫ /WT females to generate mice that were IRS-1 ϩ/Ϫ and hemizygous for the SMP8-IGF-I transgene (IRS-1 ϩ/Ϫ / SMP8-IGF-I). These mice were then bred with IRS-1 ϩ/Ϫ /WT mice to yield WT or SMP8-IGF-I mice with zero, one, or two functional IRS-1 alleles. IRS-1 genotype was identified by PCR on tail DNA. SMP8-IGF-I transgenic mice and WT mice were identified by Southern blotting on tail DNA as described previously (25) . All studies were performed in adult 50-to 60-day-old mice.
Assays of bowel growth mass, histology, and crypt cell proliferation. Animals were anesthetized with pentobarbital (100 g/g body wt). Small intestine was dissected from the ligament of Treitz to the ileocecal valve, the entire colon excluding the cecum was dissected, and the length and weight were recorded. Corresponding segments of jejunum and colon were collected for more-detailed analyses.
Protein, DNA content, and sucrase activities were assayed as previously described (15, 22) . Hematoxylin and eosin-stained sections of jejunum and colon were examined qualitatively to complement the biochemical assays. Crypt cell mitoses were measured directly in microdissected whole crypts prepared from jejunum and colon by established methods (15, 22) . The numbers of mitotic cells per crypt were assayed on 20 well-oriented crypts for each specimen by a single investigator who was unaware of the animal groupings. Apoptosis was assessed by morphological assays that have been verified to yield data equivalent to other methods such as terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling (27) . Myocyte density in muscularis layers was assayed by counting nuclei per unit area (1,000 m 2 ) on hematoxylin and eosin-stained sections.
Expression of IGF-I signaling molecules in the intestine. Mucosal scrapings and muscularis layers from jejunum and colon were homogenized in extraction buffer (50 mM HEPES, pH ϭ 7.5, 150 mM NaCl, 20 mM sodium pyrophosphate, 100 mM NaF, 1.5% Triton X-100, 10 mM EDTA) plus protease inhibitors (2 mM PMSF, 20 g/ml aprotinin) and phosphatase inhibitor (2 mM Na 3VO4). Protein extracts were immunoprecipitated with rabbit polyclonal antibodies specific for the IGF-IR ␤-chain (SC713; Santa Cruz Biotechnology, Santa Immunoprecipitates were electrophoresed on 8.5% (IGF-IR, IRS-1, and IRS-2) or 12% (Shc) SDS polyacrylamide gels and were transferred to PVDF membranes (Immobilon-P, Millipore, Bedford, MA). Immunoblots were probed with IGF-IR, IRS-1, IRS-2, or Shc antibodies. Immunoreactive proteins were identified by using the ECL detection system (PerkinElmer Life Sciences, Boston, MA) and published methods (1, 19) . Abundance of immunoprecipitated proteins was quantified by using ImageQuant (version 1.2; Molecular Dynamics, Sunnyvale, CA) software analysis of autoradiographs.
In vitro analyses. IEC-6, a nontransformed intestinal epithelial cell line from rat small intestine, was obtained from the American Type Culture Collection, cultured as previously described, and used at passages 12-20 (19) . Primary cultures of intestinal myofibroblasts were prepared from IRS-1 ϩ/ϩ and IRS-1 Ϫ/Ϫ mice as previously described (24) . Myofibroblast phenotype was confirmed by immunoblotting for ␣-smooth muscle actin and vimentin (18) . Subconfluent myofibroblasts were studied at passages 4 -6 Ϫ/Ϫ mouse were expressed as a ratio of the corresponding value in a sex-matched littermate pair. Mean ratios for different measurements of intestinal growth were compared for a significant difference from 1 by using Wilcoxon signed-rank analyses or from each other by using the Mann-Whitney U-test. Mean measurements of bowel growth (bowel weight, length, DNA, protein, mitoses, and apoptosis) in IGF-I transgenics with different IRS-1 genotype were analyzed by two-factor ANOVA for significant main effects of IRS-1 gene deletion or the IGF-I transgene and for an interaction between IRS-1 gene deletion and IGF-I transgene. A significant interaction between IRS-1 gene deletion and IGF-I transgene provides statistical evidence that IRS-1 deficiency influences the magnitude of IGF-I-induced growth. Tukey's test was used for post hoc, pair-wise comparisons between IGF-I transgenic and WT mice of each IRS-1 genotype or comparison between IRS-1 Ϫ/Ϫ /WT and IRS-1 ϩ/ϩ /WT mice. A P value of Ͻ0.05 was considered statistically significant.
The animal studies were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill. Study protocols were in compliance with the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
RESULTS
Effects of absolute IRS-1 deficiency on growth of jejunum and colon. Compared with IRS-1
ϩ/ϩ littermates, IRS-1
mice exhibited markedly reduced body weight (58 Ϯ 5% of WT littermates; P Ͻ 0.01) and decreased weight and length of entire small intestine and colon (Table 1) . More detailed analyses demonstrated reduced DNA content in the jejunal mucosa (63 Ϯ 7% of IRS-1 ϩ/ϩ littermates), whereas mucosal wet weight, protein content, and sucrase activity were unaffected by IRS-1 deficiency (Table 2A) . Crypt mitoses were reduced in the jejunal mucosa of IRS-1 Ϫ/Ϫ mice (1.9 Ϯ 0.15) relative to IRS-1 ϩ/ϩ mice (vs. 3.0 Ϯ 0.17; P Ͻ 0.05). In jejunal muscularis, wet weight, protein content, and DNA content were all significantly decreased in IRS-1 Ϫ/Ϫ mice compared with IRS-1 ϩ/ϩ littermates (Table 2A ).
In the colon of IRS-1 Ϫ/Ϫ mice, mucosal weight was significantly reduced to 75 Ϯ 7% of the value in IRS-1 ϩ/ϩ mice and mucosal weight to 67 Ϯ 5% (P Ͻ 0.05). There were parallel and proportionate decreases in DNA and protein (Table 2B) Consistent with the biochemical data, qualitative evaluation of histological sections of jejunum from IRS-1 Ϫ/Ϫ and IRS-1 ϩ/ϩ mice revealed no major effect of IRS-1 deficiency on mucosal thickness, whereas the muscularis thickness was reduced ( Fig. 1, A and B) . In the colon, thickness of both mucosa and muscularis layers was decreased in IRS-1-null mice ( mice. IGF-IR, IRS-1, IRS-2, and Shc were evaluated in the mucosa and muscularis of IRS-1 ϩ/ϩ and IRS-1 Ϫ/Ϫ jejunum and colon by immunoprecipitation followed by immunoblotting. All of the signaling molecules were low-abundance proteins requiring immunoprecipitation of at least 8 mg of total protein extract to detect IRS-1 or IRS-2, 3 mg to detect IGF-IR, and 0.2 mg to detect Shc. Figure 2 shows representative Western immunoblots. In IRS-1 ϩ/ϩ and IRS-1
mice, IGF-IR and IRS-2 were much more readily detected in colonic mucosa and muscularis (P Ͻ 0.05; n Ն 4 for both mediators) than in small intestine ( Fig. 2 ). Figure 2 also shows that in WT mice, IRS-1 is detected with higher levels in colon than small intestine (P Ͻ 0.05; n Ն 4), whereas little or no IRS-1 is detectable in small intestine or colon of IRS-1 Ϫ/Ϫ mice. To assess whether IRS-1 deficiency caused compensatory changes in the levels of IGF-IR or IRS-2 and Shc, the major alternative signaling molecules to IRS-1, levels of expression of each intermediate in mucosa or muscularis of IRS-1 ϩ/ϩ mice were expressed as a ratio of the levels in corresponding samples from IRS-1 ϩ/ϩ littermates analyzed on the same blots. Mean values across replicate samples are shown in Table 3 . IRS-1 deficiency did not significantly affect the levels of IGF-IR or IRS-2 in small intestine or colon (Table 3 ). In colon, there were small but significant increases in Shc expression in both mucosa and muscularis of IRS-1 Ϫ/Ϫ vs. IRS-1 ϩ/ϩ mice, and there was a similar but nonsignificant trend toward increased Shc in small intestine of IRS-1 Ϫ/Ϫ mice ( Table 3 ). The higher levels of expression of IGF-IR and major IGF-IR signaling substrates in colon than those found in small intestine Values are means Ϯ SE (n ϭ 9 littermate pairs). Sucrase activity is shown for only jejunum. *P Ͻ 0.05 for values in IRS-1 Ϫ/Ϫ vs. IRS-1 ϩ/ϩ mice. and the effects of IRS-1 deficiency on growth of both mucosal and muscularis layers of the colon prompted us to focus subsequent analyses on the colon.
Absolute IRS-1 deficiency impairs MT-hIGF-I-dependent growth of colonic mucosa but not muscularis. Mass of colonic mucosa and muscularis was assayed in MT-hIGF-I transgenic and WT mice with two or zero functional IRS-1 alleles to specifically test whether IRS-1 is required for trophic actions of IGF-I on the intestine in vivo. Overexpression of the MThIGF-I transgene increased mucosal wet weight (P Ͻ 0.001), protein content (P Ͻ 0.001), and DNA content (P Ͻ 0.001) in the colon of both IRS-1 ϩ/ϩ and IRS-1 Ϫ/Ϫ mice, indicating that IRS-1 is not absolutely required for IGF-I-stimulated mucosal growth (Fig. 3) . However, the magnitude of MT-hIGF-Idependent mucosal growth was significantly lower in IRS-1 Ϫ/Ϫ mice than in IRS-1 ϩ/ϩ mice (Fig. 3A) , suggesting that the absence of IRS-1 impaired the growth-promoting effects of IGF-I on colonic mucosa. Two-way ANOVA confirmed significant interactions between the IGF-I transgene and IRS-1 deficiency on mucosal growth (interaction: P Ͻ 0.001 for wet weight, protein content, and DNA content). Thus these results indicate that, in vivo, MT-hIGF-I-induced overgrowth of colonic mucosa is partially dependent on IRS-1.
As illustrated in Fig. 3B , wet weight, protein content, and DNA content in the colonic muscularis layer of IRS-1 ϩ/ϩ /MThIGF-I mice were significantly increased compared with values in IRS-1 ϩ/ϩ /WT mice. Absolute IRS-1 deficiency did not abolish the IGF-I-induced muscularis growth (Fig. 3B) . Indeed, lack of IRS-1 did not even attenuate MT-hIGF-I transgeneinduced overgrowth of the muscularis ( Fig. 3B ; interaction: wet weight, P ϭ 0.06; protein content, P ϭ 0.362; DNA content, P ϭ 0.691). These results were not due to lack of effects of IRS-1 deficiency on muscularis because two-way ANOVA revealed significant, main effects of IRS-1 deficiency to reduce all measures of muscularis mass (P Ͻ 0.001). Therefore, although IRS-1 deficiency reduces the mass of colonic muscularis, the overgrowth of the muscularis induced by MT-hIGF-I transgene overexpression in vivo does not require IRS-1 and is not attenuated by IRS-1 deficiency. Histology in Fig. 4 shows representative examples of colon from IRS-1 ϩ/ϩ /WT, IRS-1 ϩ/ϩ /MT-hIGF-I, IRS-1 Ϫ/Ϫ /WT, and IRS-1 Ϫ/Ϫ /MT-hIGF-I, which are consistent with biochemical findings.
Absolute IRS-1 deficiency does not impair SMP8-IGF-Idependent muscularis growth. To confirm that muscularis overgrowth induced by IGF-I overexpression did not depend on IRS-1, we analyzed muscularis growth in WT or SMP8-IGF-I transgenic mice with two or zero copies of IRS-1. Consistent with our previous observations (28), SMP8-IGF-I transgenic mice with two functional IRS-1 alleles showed major increases in wet weight, protein content, and DNA content of colonic muscularis compared with WT (IRS-1 ϩ/ϩ mice) (Fig. 5) . IRS-1 deficiency had no significant impact on the magnitude of SMP8-IGF-I transgene-induced growth of colonic muscularis (Fig. 5) .
IRS-1 deficiency attenuates the antiapoptotic, but not mitogenic, actions of IGF-I in colonic mucosa. As found previously for small intestine (27) , MT-hIGF transgene expression significantly increased crypt mitoses in colon of mice with two intact copies of the IRS-1 gene (Fig. 6) . Crypt mitoses were also significantly increased in colon of IRS-1-deficient MT-hIGF-I transgenics. The increase was modestly attenuated compared with IRS-1 ϩ/ϩ /MT-hIGF-I mice, but two-way ANOVA revealed no significant interaction between transgene and IRS-1 gene deletion (P ϭ 0.369). We therefore tested whether IRS-1 deficiency impaired the antiapoptotic effects of IGF-I on colonic mucosa. As found previously in small intestine, MThIGF-I transgene decreased apoptosis in colon of IRS-1 ϩ/ϩ mice (P Ͻ 0.0001), but this effect was abolished in mice homozygous for IRS-1 gene disruption (Fig. 6) . Two-way ANOVA confirmed a significant interaction (P Ͻ 0.01) between IGF-I transgene and IRS-1 deficiency on spontaneous apoptosis in colon.
Analyses of IGF-IR signaling in cultured intestinal epithelial cells and mesenchymal cells.
We tested early signaling intermediates activated by IGF-I in cultured epithelial and mesenchymal cells derived from the intestine to investigate the possible mechanisms for differential dependence on IRS-1 in the mucosa and muscularis. Nontransformed IEC-6 cells were used as a model for the intestinal epithelium because quantitative studies of IRS-1 or IRS-2 in mucosal extracts or isolated crypts proved impractical due to their low abundance and the large amounts of protein required for analyses. In IEC-6 cells, immunoblots revealed high-level expression of IRS-1, whereas IRS-2 was barely detectable (Fig. 7) . IGF-I induced robust tyrosine phosphorylation of IRS-1, with maximum phosphorylation of IRS-1 at 3 min after stimulation, whereas no tyrosine phosphorylation of IRS-2 was detected at the same (Fig. 7) or later times (unpublished data). Shc was activated by IGF-I in IEC-6 cells (Fig. 7) . Dose-dependent tyrosine phosphorylation of IGF-IR, IRS-1, IRS-2, and Shc was also examined in primary cultures of Fig. 9 ). This provides evidence for compensatory increases in the ability of IGF-I to activate the alternate signaling molecule IRS-2, but not Shc, in IRS-1-deficient intestinal mesenchymal cells.
DISCUSSION
Our results demonstrate that absolute IRS-1 deficiency significantly impairs growth of both mucosa and muscularis layers in jejunum and colon. This finding extends the evidence that IRS-1 plays a key role in mediating normal intestinal growth in vivo (1, 16) . Absolute IRS-1 deficiency led to reduced crypt-cell mitoses in both jejunum and colon. This impaired crypt-cell proliferation is consistent with in vitro findings that chicken hepatoma cells and embryonic fibroblasts require IRS-1 for normal cell proliferation (4, 20) . Interestingly, mass of small intestinal and colonic mucosa showed a differential dependence on IRS-1. Only DNA content, but not protein content, was significantly reduced in jejunal mucosa of IRS-1 Ϫ/Ϫ mice, whereas colonic mucosa showed dramatic decreases in both DNA and protein. These results indicate that jejunal mucosa may compensate more effectively than colonic mucosa for the impaired cell proliferation resulting from absolute IRS-1 deficiency by increasing the amount of protein synthesized per cell and/or cell size so that there is no discernible effect on overall mucosal mass, despite reduced cell proliferation. It seems plausible that either humoral or local factors, which act independently of IRS-1, or direct or indirect effects of nutrients may serve to maintain protein levels in jejunal mucosa during IRS-1 deficiency. Consistent with this concept, growth of jejunal mucosa is much more responsive to nutrient levels than colon (29) , and recent reports demonstrate that high calorie intake or enteral nutrient combined with trophic hormones act to increase mucosal protein more than DNA content (12, 14) . In addition, our results indicate that in the jejunal mucosa of both IRS-1 ϩ/ϩ and IRS-1 Ϫ/Ϫ mice, Shc is expressed at higher levels than IRS proteins, suggesting that it may be a predominant mediator of mucosal growth in this segment. Normal levels of sucrase in the intestine of IRS-1- null mice suggest a preferential requirement for IRS-1 as a mediator of crypt proliferation vs. enterocyte differentiation in vivo. This is consistent with data from 32D cells, in which IRS-1 is required for cell growth but not cell differentiation (23, 26) .
Our analyses of muscularis indicate that IRS-1 is required for normal cell number in muscularis layers of the intestine in vivo. This is consistent with findings in skeletal muscle cells that normal or IGF-I-dependent growth of gastrocnemius muscle requires IRS-1 (16) . Decreased thickness of intestinal muscularis layers but no significant change in cell size in IRS-1-null mice suggests that reduced cell number is responsible for the effects of IRS-1 deficiency on muscularis growth. This likely reflects decreased enteric smooth muscle cell proliferation because a lack of IRS-1 has been found to impair proliferation of other mesenchymal cell types in vitro (4) .
In intestine of IRS-1-null mice in vivo, there was no evidence for increased levels of IGF-IR or the major alternative signaling molecule, IRS-2, in the mucosa or muscularis. There appear to be tissue-specific differences in compensatory responses to IRS-1 deficiency, because in brain of IRS-1-deficient mice there is upregulation of IRS-2 levels (30). Intriguingly, specific increases in IRS-2 in the brain are also associated with minimal effects of IRS-1 deficiency on normal or IGF-I-stimulated brain growth (30) . Shc expression was modestly increased in both colonic mucosa and muscularis of IRS-1-null mice, but this was not sufficient to prevent the reduced mass and growth of these layers that was observed in IRS-1-deficient mice. We used cross-bred mice expressing IGF-I transgenes on a background of two or zero intact IRS-1 genes to specifically assess whether IRS-1 deficiency impairs the actions of IGF-1 on mucosa or muscularis in vivo. MT-hIGF-I transgene overexpression potently stimulated growth of both mucosal and muscularis layers of colon, with Ͼ200% increases in protein and DNA content in IRS-1 ϩ/ϩ /MT-hIGF-I mice vs. IRS-1 ϩ/ϩ / WT. These effects of the MT-hIGF-I transgene on the colonic mucosa are greater in magnitude than previously observed for small intestine (15) , consistent with our current observations of higher-level expression of IGF-IR and signaling molecules in the colonic vs. jejunal mucosa. The greater IGF-I responsiveness of normal colon vs. small intestinal mucosa is relevant to the increasing evidence that elevated IGF-I is a risk factor for colorectal adenoma or cancer (7).
Our observations that IRS-1 deficiency attenuates the magnitude of IGF-I-induced overgrowth of mucosa, but not muscularis, provide novel evidence for cell type-specific dependence on IRS-1 for IGF-I-induced colon growth in vivo.
In the colon, IGF-I-induced mucosal growth was only partially dependent on IRS-1, with a 50 -65% attenuation of the IGF-I-induced increases in DNA and protein in IRS-1-deficient mice. Surprisingly, this was associated with only slightly attenuated mitogenic effects of IGF-I in colonic crypts of IRS-1-null mice, whereas antiapoptotic effects of IGF-I were completely abolished by IRS-1 deficiency. Although IGF-IR/ IRS-1-activated pathways have been linked to antiapoptotic actions of IGF-I in cancer cell lines derived from the intestine, there is little or no information about in vivo signal-transduction pathways required for the antiapoptotic actions of IGF-I. Our observations demonstrate that one key IGF-I signaling molecule, IRS-1, is required for protective actions of IGF-I against crypt cell apoptosis in vivo.
The fact that IRS-1 deficiency did not impair IGF-I-dependent growth of colon muscularis demonstrates that enteric smooth muscle does not require IRS-1 for IGF-I-dependent growth. It is well known that growth of intestinal smooth muscle cells in vitro can be regulated by IGF-I (10, 31) and that IGF-I stimulation recruits IRS-1 to IGF-IR (9); however, little information is available about the primary signaling molecules that are required for IGF-I-induced enteric smooth muscle cell growth in vivo.Our prior in vivo study indicated that IRS-1 is required for IGF-I-dependent growth in skeletal muscle cells (16) , and studies in cultured embryonic fibroblasts indicate that normal growth of some mesenchymal cell types requires IRS-1 (4). Thus enteric smooth muscle cells differ from other mesenchymal cells in the lack of dependence on IRS-1. IRS-2 and Shc, which we found to be expressed in intestinal muscularis, could serve as alternate mediators of IGF-I action rather than IRS-1. The significant 80% increase in Shc levels observed in colon muscularis of IRS-1-null mice suggests that Shc may serve as an alternate signaling molecule for IRS-1 action in colon muscularis. We attempted to test whether tyrosine phosphorylation of Shc or IRS-2 was upregulated in colon muscularis of IRS-1 Ϫ/Ϫ /MT-hIGF-1 compared with IRS-1 ϩ/ϩ /MThIGF-I mice, but this proved problematic because of low-level IRS-2 expression and inability to consistently detect tyrosinephosphorylated proteins in tissue extracts. However, studies in primary mesenchymal-cell cultures demonstrate that IGF-Idependent IRS-2 activation, but not Shc activation, was dramatically upregulated in IRS-1 Ϫ/Ϫ intestinal mesenchymal cells on IGF-I stimulation. Intestinal mesenchymal cells differ from IRS-1 Ϫ/Ϫ embryonic fibroblasts, which do not show upregulated activation of alternative signaling molecules (4), further pointing to cell-and tissue-specific differences in IGF-I signaling pathways.
The lack of dependence on IRS-1 for IGF-I-induced muscularis growth in vivo appears paradoxical given the reduced mass of enteric smooth muscle layers in IRS-1 Ϫ/Ϫ mice relative to IRS-1 ϩ/ϩ mice. This suggests that normal growth of intestinal muscularis is regulated by other IRS-1-linked hormones than IGF-I, which could include growth hormone and angiotensin II, which both have trophic effects on smooth muscle and both activate IRS-1 (6, 17) .
Normal MT-hIGF-1-mediated muscularis overgrowth in IRS-1 Ϫ/Ϫ mice could reflect some compensatory responses to long-term elevations of circulating IGF-I that occur in these transgenics. We therefore used a second model, SMP8-IGF-I/WT and SMP8-IGF-I/IRS-1 Ϫ/Ϫ mice, to directly assess the requirement of the intestine for IRS-1 in mediating autocrine/ paracrine actions of IGF-I expressed specifically in the intestinal muscularis layers. Our results in these mice provide independent confirmation that IRS-1 is not required for IGF-I-mediated growth of the muscularis. SMP8-IGF-I transgenics show no increase in plasma levels of IGF-I (25, 28) and, therefore, results in these mice are not confounded by secondary effects that could occur due to long-term effects of elevated circulating IGF-I.
We can only speculate on the biological reason why the colonic epithelium should have greater dependence on IRS-1 for growth-promoting and antiapoptotic actions of IGF-I compared with muscularis. Low apoptosis within colonic crypts is linked to increased risk the development of precancerous adenomatous lesions within the colonic epithelium (8) , and much evidence suggests a role of IGF-I in colon cancer risk (7) . The dependence of the epithelium but not muscularis on IRS-1 may therefore serve as a protective mechanism against protumorigenic effects of IRS-1.
In conclusion, our findings provide new in vivo evidence for cell type-specific requirements for IRS-1 as a mediator of normal or IGF-I-induced intestinal growth that could not have been predicted from in vitro findings or observations in other tissues. Specifically, 1) normal crypt cell mitoses in colonic and jejunal mucosa require IRS-1; 2) in jejunal mucosa, normal DNA but not protein or sucrase activity in the mucosa requires IRS-1, whereas in colon, DNA and protein content are both affected by IRS-1 deficiency; 3) using a cross-breeding approach to generate mice that overexpress IGF-I on a background of normal or zero levels of IRS-1, we demonstrated that mucosa, but not muscularis, shows partial dependence on IRS-1 for IGF-I-induced growth in vivo; 4) the mucosal growth deficit in IRS-1 Ϫ/Ϫ /MT-hIGF-I mice involves impaired ability of IGF-I to reduce apoptosis rather than impaired mitogenic actions; 5) in vitro findings indicate that IRS-1 is used in preference to IRS-2 to mediate IGF-I action in intestinal epithelial cells, whereas intestinal mesenchymal cells use both IRS-1 and IRS-2 to mediate IGF-I action; and 6) activation of IRS-2 is upregulated in IRS-1-deficient intestinal mesenchymal cells. 
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